James P. Allison

James P. Allison is a Nobel Laureate (2018) who discovered that blocking CTLA-4, a T cell inhibitory receptor, could unleash anti-tumor immune responses. This fundamental insight led to the development of ipilimumab, the first immune checkpoint inhibitor approved by the FDA. Allison's work established the paradigm of checkpoint blockade immunotherapy that has transformed cancer treatment, with checkpoint inhibitors now approved across dozens of cancer types.

James P. Allison是2018年诺贝尔奖获得者，他发现阻断CTLA-4（一种T细胞抑制性受体）可以释放抗肿瘤免疫反应。这一基础性发现导致了ipilimumab的开发，这是第一个FDA批准的免疫检查点抑制剂。Allison的工作确立了检查点阻断免疫治疗范式，彻底改变了癌症治疗，检查点抑制剂现已获批用于数十种癌症类型。